Health tech startup Signos has announced a $20 million funding round to enhance its position in the growing weight-loss market driven by GLP-1 medications, while also expanding its partnership with Dexcom, a medical device leader. This funding, supported by notable investors such as Google Ventures and Blue Cross Blue Shield of Alabama, will facilitate the integration of Signos’ AI-powered glucose monitoring system, which became the first of its kind cleared by the FDA in 2025. Signos aims to provide personalized health recommendations by analyzing users’ glucose data in real-time, thereby helping them manage their weight effectively, whether used alongside GLP-1 drugs like Wegovy and Zepbound or as an independent solution.
Dexcom: Dexcom is a medical device company that produces continuous glucose monitoring technology primarily for diabetes management. It recently invested in Signos and entered a new distribution agreement to offer Signos’ subscription plans directly to consumers through its platform. The partnership extends Dexcom’s biosensing capabilities into AI-driven guidance for weight loss and metabolic health beyond diabetes.
Signos: Signos is a health tech startup that develops an AI-powered glucose monitoring system to support healthy weight loss by translating real-time glucose data into personalized lifestyle recommendations. The company recently announced a funding round and expanded its partnership with Dexcom to increase distribution of its subscription plans. Its platform uses continuous glucose monitoring to help users understand how meals, sleep, and stress affect their metabolic health and to build sustainable habits.
Google Ventures: Google Ventures is the venture capital arm of Google that invests in innovative health tech and other growth companies. It participated in Signos’ latest funding round alongside Dexcom and Blue Cross Blue Shield of Alabama. The investment supports Signos’ expansion in the AI-enabled glucose tracking space for weight management.
Sharam Fouladgar-Mercer: Sharam Fouladgar-Mercer is the CEO of Signos, where he leads development of AI-driven glucose insights for weight management. He recently highlighted the company’s partnership with Dexcom and the value of translating biosensor data into practical user guidance for behavior change. His comments emphasize AI’s role in personalizing metabolic feedback without requiring advanced statistical expertise.
Blue Cross Blue Shield of Alabama: Blue Cross Blue Shield of Alabama is a regional health insurance provider that invests in health technology companies. It participated in Signos’ recent funding round to back the startup’s growth in the weight-loss and metabolic health market. The involvement aligns with broader efforts to support preventive health solutions.
`json
{
“GLP-1 Integration”: “Signos’ platform complements GLP-1 medications by offering metabolic feedback that enhances user optimization of treatments like Wegovy and Zepbound.”,
“Regulatory Milestone”: “Signos has been granted FDA clearance as the first AI-driven glucose monitoring system focused on promoting healthy weight loss.”,
“Technology Expansion”: “The integration of Dexcom’s biosensor data with Signos’ AI technology extends glucose monitoring beyond diabetes management into areas of weight loss and habit development.”
}
`